Colombia, Chile and Peru Wilson’s Disease Treatment Market Analysis & Forecast: 2026-2033
The Colombia, Chile and Peru Wilson’s Disease Treatment market size is estimated to reach around USD 0.80 Mn in 2026 and is projected to grow at a CAGR of 5.1% during the forecast period (2026-2033), totalling USD 1.19 Mn by 2033.
Colombia, Chile and Peru Wilson’s Disease Treatment market is projected to grow steadily during the forecast period. This is primarily due to the adoption of genetic testing for early diagnosis. Wilson’s Disease, a rare genetic disorder characterized by copper accumulation leading to liver and neurological damage, poses considerable diagnostic challenges, often leading to delayed treatment. In recent years, these countries have increasingly integrated genetic testing into clinical practice, facilitating earlier and more accurate identification of affected individuals, particularly in at-risk populations.
Wilson’s Disease, a rare genetic disorder characterized by excessive accumulation of copper in the body, primarily requires therapies that facilitate copper removal or prevent its absorption. Chelation agents, such as penicillamine and trientine, work by binding excess copper and facilitating its excretion, while zinc-based therapies inhibit the absorption of copper from the gastrointestinal tract.
Increasing awareness of Wilson's disease has played a pivotal role in driving the growth of the Wilson’s Disease Treatment Market across Colombia, Chile, and Peru. Historically, Wilson’s disease, a rare genetic disorder characterized by excessive copper accumulation in tissues, remained underdiagnosed in these countries due to limited public and physician awareness, coupled with inadequate diagnostic facilities. For instance, to address these issues, the Wilson Disease Association (WDA) marked the 2nd International Wilson Disease Awareness Day on December 6, 2025, to celebrate the progress made in the global Wilson disease community. This event highlights the efforts to raise awareness about the disease, which affects approximately 1 in 30,000 people worldwide.
Wilson’s disease is a rare genetic disorder characterized by excess copper stored in various body tissues, particularly in the liver, brain, and corneas of the eyes. The disease is progressive, and if left untreated, it may cause liver (hepatic) disease, central nervous system dysfunction, and death. The signs and symptoms of Wilson’s disease usually first appear between the ages of 6 and 45 years; however, they most often begin during the teenage years. Wilson’s disease is also known as hepatolenticular degeneration and lenticular degeneration.
|
Current Event |
Description and its Impact |
|
Rising Healthcare Expenditures and Government Health Investment |
|
|
Government-Backed Insurance Programs and Policy Support |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Based on drugs, D- Penicillamine segment is expected to dominate the market, with a revenue share of about 46% in 2026. D-Penicillamine has been the cornerstone of Wilson’s Disease treatment for decades, primarily due to its mechanism as a chelating agent that binds to excess copper in the body, facilitating its excretion through the urine.
This drug’s widespread recognition among healthcare professionals across Colombia, Chile, and Peru is bolstered by numerous clinical guidelines and treatment protocols established by regional health authorities and international organizations, such as the Wilson Disease Association and the Pan American Health Organization (PAHO).
By distribution channel, hospital pharmacies segment is slated to hold a dominant position in market over the forecast period. Hospital pharmacies in these countries serve as primary hubs for the dissemination of specialized medications like chelating agents (e.g., penicillamine and trientine) and zinc salts, which are critical in managing copper accumulation in Wilson’s Disease patients.
The dominance of Hospital Pharmacies is strongly linked to the fact that treatment initiation and monitoring for Wilson’s Disease necessitate close clinical supervision and periodic evaluation of biochemical parameters, activities primarily coordinated within hospital settings. For example, in Colombia, major tertiary care hospitals such as the Fundación Santa Fe de Bogotá and Clínica Universitaria Colombia are equipped with specialized liver units and provide comprehensive care pathways for patients with genetic liver disorders, including Wilson’s Disease.
The Colombia is expected to remain the market leader, accounting for a share of about 85% in 2026. The country has established one of the most comprehensive healthcare systems in Latin America, known for wide accessibility, government-supported health initiatives, and a robust network of healthcare facilities specializing in rare diseases like Wilson’s Disease. A key driver of this success has been the country’s commitment to rare disease awareness and treatment.
For instance, as detailed in an article published by Uncommon Cure in December 2024, Law 1392, passed in 2010, mandates social protection for individuals with rare diseases, ensuring they have access to medicines and diagnostics, while promoting the development of centers of excellence. In line with this law, Colombia created a national registry for rare diseases, which, as of 2017, included over 13,000 patients across 653 different conditions. Moreover, the Federación Colombiana de Enfermedades Raras (FECOER) plays an active role in advocacy and policy development, contributing to growing public awareness. The country has also participated in Rare Disease Day since 2009, raising awareness and encouraging collaboration among stakeholders.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 0.80 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.1% | 2033 Value Projection: | USD 1.19 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Alexion Pharmaceutical, Inc., and Sanofi S.A. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Rising healthcare expenditures in South American nations, particularly Colombia, Chile, and Peru, have significantly contributed to the expansion of the Wilson’s Disease treatment market in these countries. Governments in this region have been increasing their budgets to improve healthcare infrastructure and ensure broader access to specialized treatments for rare genetic disorders like Wilson’s Disease.
According to the OECD 2025 report, many Central and Eastern European countries, as well as newer OECD members in Latin America, spend between 6-9% of their GDP on healthcare. Mexico and Türkiye are exceptions, with spending below 6% of their GDP on healthcare. As healthcare investments continue to rise in nations like Colombia, governments are focusing on expanding access to specialized treatments for conditions like Wilson’s Disease, which is driving market growth in these regions.
Targeted government initiatives in Colombia, Chile, and Peru have significantly catalyzed advancements in the management of rare diseases such as Wilson’s Disease, thereby positively influencing the development of the Wilson’s Disease treatment market in these countries. Governments in these Latin American nations have increasingly prioritized rare disease policies, focusing on enhancing early diagnosis, patient registries, and access to specialized treatment.
For example, Chile’s Ministry of Health has implemented a national strategy specifically aimed at rare diseases, which includes subsidized access to medications and improved diagnostic infrastructure at public hospitals. This approach ensures that patients with Wilson’s Disease, a rare genetic disorder characterized by copper accumulation, receive timely and adequate treatment.
The emergence of novel therapeutic approaches is fundamentally reshaping treatment paradigms in the Colombia, Chile, and Peru Wilson's Disease market by challenging the dominance of conventional chelating agents that have been the standard of care for decades. Traditionally, D-Penicillamine and Trientine have served as the primary copper-removal therapies, but the pharmaceutical industry is now actively exploring alternative delivery systems and mechanism-based interventions.
The development of enhanced patient support systems and diagnostic tools represents a critical opportunity to address the significant diagnostic gaps currently limiting Wilson's disease detection and treatment in Colombia, Chile, and Peru. Wilson's disease remains an orphan disease in Colombia with insufficient epidemiological understanding despite its potential for serious complications when left undiagnosed.
The growing demand for Wilson’s Disease treatment in Colombia, Chile, and Peru is being significantly bolstered by the expansion of national health insurance schemes and strategic partnerships aimed at enhancing patient care in remote and underserved regions. These countries have increasingly recognized the need to address rare and chronic diseases like Wilson's Disease, which requires lifelong management involving chelation therapy and other treatments.
Share
Share
About Author
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
